Treatment of Obstructive Lung Disease

Diagnosis and Interpretation of Spirometry Results

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria classify a patient with an FEV1 of 80% predicted as having mild COPD (GOLD 1) 1
A FEV1/FVC ratio of 56.5% confirms airflow obstruction, as it is below the threshold of 70% used to diagnose COPD 2, 3
The European Respiratory Society recommends using post-bronchodilator spirometry to confirm the diagnosis of COPD, as pre-bronchodilator measurements may overestimate COPD prevalence by up to 36% 4, 2

The American Thoracic Society recommends initiating treatment with a long-acting bronchodilator (either LAMA or LABA) for patients with mild COPD (FEV1 ≥80% predicted) and symptoms 5, 1
The European Respiratory Society suggests that short-acting bronchodilators should be prescribed as rescue medication for symptom relief 1
Inhaled corticosteroids (ICS) are recommended for patients with more severe disease or frequent exacerbations, according to the GOLD guidelines 1

Long-acting inhaled therapies have been shown to reduce exacerbations by 13% to 25% compared to placebo, with a moderate strength of evidence 5
Bronchodilators improve lung function parameters and dyspnea even when the improvement in FEV1 is modest, with a high strength of evidence 6
Volume responses to bronchodilators (improvement in FVC) may be clinically significant even without substantial FEV1 improvement, with a moderate strength of evidence 6

The GOLD guidelines recommend scheduling follow-up in 4-6 weeks to assess response to therapy, inhaler technique, symptom control, and need for treatment adjustment 1, 2
Annual spirometry is recommended to monitor disease progression, according to the European Respiratory Society 1, 2

Repeat spirometry on a separate occasion when the post‑bronchodilator FEV₁/FVC ratio is 0.60–0.80 to verify persistent airflow obstruction; the recommended interval for repeat testing is 3–6 months. (European Respiratory Society) 7
If the initial post‑bronchodilator FEV₁/FVC ratio is < 0.60, repeat testing is less critical because the likelihood of a spontaneous rise above 0.70 is very low. (European Respiratory Society) 8
A definitive diagnosis requires (1) spirometric confirmation of obstruction, (2) a relevant exposure history (e.g., tobacco or occupational exposures), and (3) compatible respiratory symptoms. (European Respiratory Society) 9

Individuals whose pre‑bronchodilator FEV₁/FVC < 0.70 but post‑bronchodilator FEV₁/FVC ≥ 0.70 (“flow responders”) have an increased risk of progressing to persistent COPD. (European Respiratory Society) 7
For flow responders, close follow‑up with repeat spirometry every 3–6 months is recommended to detect progression early. (European Respiratory Society) 8
The risk of progression is especially high in patients who continue smoking or whose FEV₁/FVC values are close to the 0.70 threshold. (European Respiratory Society) 10

Using a fixed FEV₁/FVC < 0.70 cutoff without clinical context (age, symptoms, exposure history) may lead to over‑diagnosis of COPD in older adults; clinicians should adjust interpretation accordingly. (European Respiratory Society) 9